This story is from the CurrentWire archive. Coverage details reflect the last time it was updated.
Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide
TORONTO, Aug. 31, 2026 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has received central Institutional Review Board (“IRB”) approval of the protocol and related study documents for the Company’s ongoing Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (“CS-AKI”). Arch recently announced […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 7 minutes later, on .
Filed under General · US & Canada · Press release. Topics extracted from this report, with other live CurrentWire stories mentioning each: Toronto (1), United States (88), Central IRB Approval (none), Support US (none), Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial (none), LSALT Peptide (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.